Anti-human epidermal growth factor 2 (HER2) therapy has been approved as a standard practice for patients with HER2-positive breast cancer, leading to an improvement of patient outcome during the past decade [1], [2], [3]. The gene discussed is ERBB2; the disease is breast carcinoma.